NACCO INDUSTRIES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that NACCO INDUSTRIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $104.78M | Mar 7, 2018 |
| FY2016 | Dec 31, 2016 | $284.22M | Mar 1, 2017 |
| FY2016 | Sep 30, 2016 | $220.79M | Mar 1, 2017 |
| FY2016 | Jun 30, 2016 | $178.01M | Mar 1, 2017 |
| FY2016 | Mar 31, 2016 | $173.42M | Mar 1, 2017 |
| FY2016 | Dec 31, 2015 | $286.52M | Mar 1, 2017 |
| FY2016 | Sep 30, 2015 | $239.11M | Mar 1, 2017 |
| FY2016 | Jun 30, 2015 | $196.50M | Mar 1, 2017 |
| FY2016 | Mar 31, 2015 | $193.73M | Mar 1, 2017 |
| FY2015 | Dec 31, 2014 | $297.29M | Mar 2, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $277.20M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $237.71M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $214.79M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $241.72M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $191.85M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $128.43M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $140.99M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $135.38M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $104.78M | Mar 6, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.47M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $29.76M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $14.59M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $67.84M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $43.45M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $16.97M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $31.13M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $29.97M | Mar 4, 2020 |
| FY2017 | Dec 31, 2017 | $5.29M | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | $2.48M | Mar 7, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.57M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $33.74M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($39.59M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $74.16M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $48.13M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $14.79M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $39.63M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $34.79M | Mar 4, 2020 |
| FY2017 | Dec 31, 2017 | $10.17M | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | $8.40M | Mar 7, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.98M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $35.71M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | ($70.14M) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $69.99M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $55.41M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $13.45M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $38.82M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $43.62M | Mar 4, 2020 |
| FY2017 | Dec 31, 2017 | $6.51M | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | $6.99M | Mar 7, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $9.70M | Mar 1, 2017 |
| FY2016 | Dec 31, 2015 | $9.60M | Mar 1, 2017 |
| FY2016 | Dec 31, 2014 | $9.60M | Mar 1, 2017 |
| FY2015 | Dec 31, 2013 | $8.10M | Mar 2, 2016 |
| FY2014 | Dec 31, 2012 | $7.50M | Mar 9, 2015 |
| FY2013 | Dec 31, 2011 | $7.40M | Mar 4, 2014 |
| FY2012 | Dec 31, 2010 | $7.60M | Mar 6, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.85M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $69.75M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $65.62M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $63.91M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $55.72M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $53.06M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $53.78M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $49.19M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $47.49M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $48.86M | Mar 7, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.91M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $22.29M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $54.49M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $67.74M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $74.88M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($2.49M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $52.78M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $54.62M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $41.31M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $93.94M | Mar 7, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.63M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $54.71M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $45.41M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $42.52M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $39.23M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $30.19M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $24.66M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $20.93M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $15.70M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $10.17M | Mar 7, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $661.23M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $631.69M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $539.71M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $568.07M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $507.22M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $476.18M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $444.77M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $376.99M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $389.55M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $668.02M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $231.99M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $226.74M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $157.37M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $141.11M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $155.10M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $175.56M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $155.38M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $126.29M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $170.10M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $447.73M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $429.24M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $404.95M | Mar 4, 2026 |
| FY2025 | Dec 31, 2023 | $382.34M | Mar 4, 2026 |
| FY2024 | Dec 31, 2022 | $426.97M | Mar 5, 2025 |
| FY2023 | Dec 31, 2021 | $352.12M | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | $300.62M | Mar 15, 2023 |
| FY2021 | Dec 31, 2019 | $289.39M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $250.70M | Mar 3, 2021 |
| FY2018 | Dec 31, 2017 | $219.45M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $220.29M | Mar 7, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Dec 31, 2016 | $6.25M | Mar 1, 2017 |
| FY2016 | Dec 31, 2015 | $6.25M | Mar 1, 2017 |
| FY2015 | Dec 31, 2014 | $6.25M | Mar 2, 2016 |
| FY2014 | Dec 31, 2013 | $0 | Mar 9, 2015 |
| FY2013 | Dec 31, 2012 | $6.40M | Mar 4, 2014 |
| FY2012 | Dec 31, 2011 | $0 | Mar 6, 2013 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $381.13M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $373.36M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $355.87M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $404.92M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $336.78M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $294.27M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $284.85M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $250.35M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $216.49M | Mar 6, 2019 |
| FY2017 | Dec 31, 2016 | $239.44M | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.71M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $72.83M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $85.11M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $110.75M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $86.01M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $88.45M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $122.89M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $85.26M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $101.60M | Mar 6, 2019 |
| FY2018 | Dec 31, 2016 | $69.31M | Mar 6, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.84M | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | $99.40M | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | $35.80M | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | $18.90M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $20.40M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $45.00M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $24.30M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $10.60M | Mar 4, 2020 |
| FY2018 | Dec 31, 2017 | $56.70M | Mar 6, 2019 |
| FY2016 | Dec 31, 2016 | $126.09M | Mar 1, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 10 | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 6 | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 2 | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 5 | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 5 | Mar 4, 2020 |
| FY2017 | Dec 31, 2017 | 1 | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | 1 | Mar 7, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2 | Mar 4, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Mar 4, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Mar 5, 2025 |
| FY2023 | Dec 31, 2022 | 10 | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 6 | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | 2 | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 5 | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 5 | Mar 4, 2020 |
| FY2017 | Dec 31, 2017 | 1 | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | 1 | Mar 7, 2018 |